



Living Cell Technologies Limited Company Announcement

LCT Presents Novel Parkinson's Disease Treatment Results

20 March 2012: Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY)

Today, LCT's Medical Director, Emeritus Professor Robert Elliott, presented for the first time the results of pre-clinical trials of NTCELL therapy in non-human primate models of Parkinson's disease at BioPharma Asia 2012.

LCT is a global leader in developing cell transplant therapies to treat chronic disease and NTCELL is LCT's lead product for treatment of neurodegenerative disorders. NTCELL has been developed using LCT's pioneering animal-cell-based transplantation and encapsulation platform.

The pre-clinical studies were performed in animals in which a Parkinson's-like condition had been induced. In all of the studies, transplantation of NTCELL into the affected brain regions reduced movement disorders and neurological defects associated with the disease compared to controls, which received only empty capsules. The improvements in symptoms were seen within two weeks and persisted for at least six months, the end-point of the trial. Microscopic analysis of both treated and untreated brain regions clearly showed an increase in the number of dopamine producing neurons in the NTCELL treated subjects compared to controls. In addition, there was no cellular or pathological evidence of inflammation or other adverse event.

Professor Robert Elliott said, "Today we have presented a comprehensive suite of pre-clinical data in small animal and non-human primate studies which show an astonishing recovery of the part of the brain affected in Parkinson's disease, as well as a more than 50% improvement in the devastating movement and neurological symptoms of the disease. We are now compiling an application to New Zealand's medicines safety authority, Medsafe, to start Phase I clinical trials in Parkinson's patients. Pending regulatory authorisation, LCT expects to begin these trials by the end of Q1 2013."

Dr Andrea Grant, Chief Executive Officer of LCT said, "BioPharma Asia is the leading forum through which the most influential decision makers in the Asian and global biopharmaceutical industry forge partnerships. We are delighted to have been invited to present our unprecedented results of NTCELL in Parkinson's as a plenary."

Ends

For further information: www.lctglobal.com

At the company:

Andrea Grant, Chief Executive
Tel: +64 9 276 2690
Mobile: +64 21 469000
agrant@lctglobal.com

Media enquiries:

Sally Raudon
Botica Butler Raudon Partners
Tel: +64 9 303 3862
Mobile: +64 21 402 502
sallyr@botica.co.nz

To see Professor Robert Elliott's presentation to BioPharma Asia please visit www.lctglobal.com.

About Living Cell Technologies

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company holds 50% of Diatrantz Otsuka Limited which owns a bio-certified pig herd that it uses as a source of cells and DIABECCELL® which is designed to help normalise the lives of people with unstable Type 1 diabetes, especially those suffering from life-threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. Using breakthrough proprietary microencapsulation technology, IMMUPEL™, which enables implantation of cell-based therapeutics without immunosuppression, LCT is developing NTCELL, a choroid plexus cell product which is currently in preclinical development to treat neurodegenerative diseases such as Parkinson's disease, Huntington's disease, stroke, and hearing loss. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company holds 50% of Diatrantz Otsuka Limited which owns a bio-certified pig herd that it uses as a source of cells and DIABECCELL® which is designed to help normalise the lives of people with unstable Type 1 diabetes, especially those suffering from life-threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. Using breakthrough proprietary microencapsulation technology, IMMUPEL™, which enables implantation of cell-based therapeutics without immunosuppression, LCT is developing NTCELL, a choroid plexus cell product which is currently in preclinical development to treat neurodegenerative diseases such as Parkinson's disease, Huntington's disease, stroke, and hearing loss. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.